Neurostar RTMS denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for neurostar rtms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied NeuroStar TMS as Experimental — and How to Fight It

NeuroStar TMS (transcranial magnetic stimulation) received FDA 510(k) clearance for the treatment of major depressive disorder in adults more than a decade ago and has since received additional FDA clearances for other indications. An "experimental or investigational" denial from UnitedHealthcare is a serious but commonly appealed finding — and it is frequently overturned when the clinical evidence base is properly documented.

### Why This Denial Is Appealable

Insurers define "experimental" or "investigational" using their own internal criteria, which typically require the absence of FDA clearance, insufficient peer-reviewed evidence, or lack of established clinical consensus. For NeuroStar TMS in its FDA-cleared indications, none of these factors is typically present. Your appeal should directly rebut each element of UHC's experimental/investigational definition by pointing to the FDA clearance history, published peer-reviewed literature, and endorsements or coverage guidance from the relevant national psychiatric and medical organizations. ACA Section 2719 and ERISA Section 503 require UHC to provide a specific clinical basis for any adverse determination and to review all evidence you submit.

### Your Appeal Timeline

• Internal appeal: Deadlines are printed on your denial letter. Pre-service decisions are required within 30 days; post-service within 60 days.
• External review: After an adverse internal decision, you typically have four months to file for independent external review. External reviewers are trained to evaluate experimental/investigational denials and their decisions are binding on UHC.
• Expedited option: Available within 72 hours if your health would be seriously jeopardized by standard timing.

### Documentation to Gather

1. FDA clearance documentation — the FDA 510(k) clearance letter(s) for NeuroStar TMS in your specific indication, available from the FDA's public device database. 2. Diagnosis and severity documentation — psychiatric records confirming your diagnosis, symptom severity, and functional impairment. 3. Clinical guideline support — a citation or printout of the relevant national guideline organization's (e.g., applicable APA or AHRQ) position on TMS as a treatment option for your diagnosis. 4. Prescriber letter — a detailed letter from your psychiatrist explaining that TMS is an accepted, evidence-based, and clinically indicated treatment for your condition, citing the FDA clearance and professional society guidance. 5. Prior-treatment history — documentation of previous treatments tried and their inadequate outcomes, establishing the medical necessity context.

### Criteria-Mapping Structure

Request UHC's written experimental/investigational policy definition in full. List every element UHC must find to classify a treatment as experimental. Then, for each element, provide a direct rebuttal with supporting evidence (FDA clearance number, peer-reviewed publication, guideline organization statement). This structured rebuttal is the most effective format for an experimental-therapy appeal because it forces the reviewer to address each point individually rather than rely on a categorical determination.